NCT07707271Recruiting
Continuous Versus High Intensity Interval Exercise in Chronic Obstructive Pulmonary Disease
Changes in Brain Oxygenation, Cadiopulmonary Parameters and Autonomic Nervous System Function During Moderate Intensity Continuous Versus High Intensity Interval Exercise in Chronic Obstructive Pulmonary Disease
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
Chronic Obstructive Pulmonary Disease (COPD) is characterized by exercise intolerance, which is a prognostic factor of disease severity and mortality and is usually attributed to ventilatory limitations. Emerging evidence indicates that cerebral oxygenation may also be an important contributor, being impaired both at rest and during exercise in COPD patients. Furthermore, abnormal systemic hemodynamic responses and autonomic nervous system (ANS) dysfunction have been observed, which may further impair cerebral oxygenation. The type of exercise training applied in pulmonary rehabilitation (continuous versus interval) appears to influence these mechanisms differently, yet evidence on their impact on cerebral oxygenation in COPD remains scarce. The aim of this study is to compare, for the first time, the acute changes in cerebral oxygenation, CPET parameters, systemic hemodynamic responses, and autonomic responses in patients with COPD who undergo a high-intensity interval aerobic exercise (HIIE) protocol versus a moderate-intensity continuous aerobic exercise (MICE) protocol. These findings will have important clinical implications, as they may guide the choice of the most appropriate exercise modality in pulmonary rehabilitation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 26 Jun 2026
- Start date
- 15 Jun 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- George Papanicolaou Hospital
- Diseases
- COPD
- NCT number
- NCT07707271
What you commit to
- Study type: Interventional
- Planned participants: 12
- From 15 Jun 2026 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent respiratory infection or exacerbation (as indicated by deterioration of respiratory symptoms, hospital admission and/or change in medication within the previous month), within the past 3 months
- Changes in COPD medication with the past month
Other illness
- History of asthma and/or reversible airway obstruction (post bronchodilation FEV1/ FVC \>0.7)
- Pulmonary hypertension
- Severe peripheral artery disease
- Active acute or chronic infectious diseases
- Active malignant disease or hematologic disorder under treatment
- History of neuromuscular disorder
- History of severe intellectual disability or mental disorder
- Any contradiction to moderate-high intensity exercise or cardiopulmonary exercise testing according to ATS/ACCP guidelines, such as: myocardial infarction within the past 6 months, unstable angina, syncope, symptomatic severe aortic stenosis, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute pulmonary embolus or pulmonary infarction, thrombosis of lower extremities, suspected dissecting aneurysm, pulmonary edema, severe untreated arterial hypertension at rest (\> 200 mm Hg systolic, \> 120 mm Hg diastolic blood pressure), orthopedic impairment that compromises exercise performance.
Lab values
- Congestive heart failure (Left Ventricle Ejection Fraction \<50% in recent echocardiography)
- Chronic Kidney disease with eGFR \< 30 ml/min (KDIGO stages 3b, 4 ,5)
Who the study is looking for
- Clinical diagnosis of COPD based on smoking history (pack/years) or exposure to other risk factors and post bronchodilation forced expiratory volume (FEV1) to forced vital capacity (FVC) ratio \<0.7
- Resting arterial oxygen partial pressure at room air \>60 mmHg, according to recent (within a week) arterial blood gases assessment
- Disease being stable and treated optimal, based on current GOLD guidelines.
- Provision of informed written signed consent prior to study entry
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| George Papanikolaou General Hoapital of Thessaloniki Coordinator of this site? Confirm its status | Thessaloniki | Greece | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.